Adverse Events of Fluoxetine: Postmarketing Compared With Premarketing Clinical Trials

View This PDF

NB: This article is only available as a PDF.

Letter to the Editor

Sir: A prevalent perception exists among clinical pharmacologists and clinicians that the burden of adverse events is higher when a drug is utilized in the natural clinical environment than when used in premarketing clinical trials. The postmarketing study by Zajecka et al., which reported on the adverse events of fluoxetine, affords the opportunity to test this perception.

J Clin Psychiatry 2000;61(11):874